RESUMO
Concentrations were studied of 58Co in the solid Ehrlich ascites tumour, blood, muscle and bone of male Swiss mice administered as complexed with total bleomycin commercially available and its isolated fractions A2, B2, demethyl A2, A1, A5, B4 and bleomycinic acid. The tumour/non-tumour ratios were determined 24 hrs after injection of the complexes. The ratios for fraction A2, B2 and total bleomycin were very close to each other. The remaining fractions showed lower values of the ratios. These results suggest that it is unlikely that any of the fractions studied are superior to total labelled bleomycin with respect to tumour scintigraphy.
Assuntos
Bleomicina/metabolismo , Carcinoma de Ehrlich/metabolismo , Animais , Bleomicina/sangue , Osso e Ossos/metabolismo , Radioisótopos de Cobalto , Camundongos , Músculos/metabolismo , Transplante de NeoplasiasRESUMO
Tumor and normal tissue uptake of 51Cr- or 57Co-labelled bleomycin (BLEO) and tallysomycin (TLM) was compared in female solid Ehrlich ascites tumor mice of Swiss strain. The complexes were administered intraperitoneally: 30-50 micrograms of each complex with an activity of 40-120 microCi. Activity distribution factors (ADF) and tumor/non-tumor ratios for blood, bone, skeletal muscles, kidneys and liver were determined. The ratios were generally higher for complexes labelled with 57Co than for the 51Cr-labelled ones; bleomycin appears equivalent or superior to tallysomycin.
